Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: Multicenter experience with an alternative salvage strategy

Leukemia

Volumn 25, Issue 5, 2011, Pages 880-883

  Tuve, S ^a   Gayoso, J ^b   Scheid, C ^c   Radke, J ^a   Kiani, A ^d   Serrano, D ^b   Platzbecker, U ^a   Rodriguez Macias G ^b   Wermke, M ^a   Holtick, U ^c   Balsalobre, P ^b   Middeke, J M ^a   Shayegi, N ^a   Chemnitz, J M ^c   Krause, A ^c   Gruner, N ^a   Fussel M ^e   Schetelig, J ^a   Thiede, C ^a   Ehninger, G ^a,f   Hallek, M ^c   Diez Martin J L ^b   Bornhauser M ^a,f   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d INSTITUTE OF PATHOLOGY   (Germany)

^e DKMS Life Science Lab GmbH   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CD34 SELECTION; CELL KILLING; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOPENIA; DONOR; DRUG MEGADOSE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDY; HAPLOTYPE; HISTOCOMPATIBILITY; HLA MATCHING; HLA MISMATCH; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LOW DRUG DOSE; MALE; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 79955794235     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.11     Document Type: Letter

References (7)

1. Schetelig J, Kiani A, Schmitz M, Ehninger G, Bornhäuser M. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunol Immunother 2005; 54: 1043-1058. (Pubitemid 41396810)
2. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophos-phamide to promote graft-host tolerance after allogeneic hemato-poietic stem cell transplantation. Immunol Res 2010; 47: 65-77.
3. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650. (Pubitemid 351664058)
4. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post-transplantation cyclo-phosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482-489.
5. Mayumi H, Himeno K, Tokuda N, Nomoto K. Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide- induced tolerance in an H-2 haplotype-identical strain combination. Transplant Proc 1986; 18: 363-369. (Pubitemid 16113722)
6. Nomoto K, Eto M, Yanaga K, Nishimura Y, Maeda T. Interference with cyclophosphamide-induced skin allograft tolerance by cyclo-sporin A. J Immunol 1992; 149: 2668-2674.
7. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)